Leap Therapeutics (NASDAQ: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap's second clinical candidate, TRX518, is a humanized GITR agonist monoclonal antibody designed to enhance the immune system's anti-tumor response that is in advanced solid tumor studies. Source
No articles found.
NanoVibronix Inc. is a medical device company that is focused on creating medical ...
NanoVibronix Inc. is a medical device company t...
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
Health Journal is a leader and influencer in health publishing in Virginia, USA an...
Health Journal is a leader and influencer in he...
Ionis is a sustainably profitable, multi-product company with a pipeline of more t...
Ionis is a sustainably profitable, multi-produc...
Aduro is dedicated to its mission to discover, develop, and commercialize immunoth...
Aduro is dedicated to its mission to discover, ...
Avid Bioservices is a dedicated contract development and manufacturing organizatio...
Avid Bioservices is a dedicated contract develo...
CTI BioPharma is a biopharmaceutical company focused on the acquisition, developme...
CTI BioPharma is a biopharmaceutical company fo...
Join the National Investor Network and get the latest information with your interests in mind.